Article · 24 Jan 2024
Conference abstractPublished 15 Apr 2022
Tumor Necrosis Factor Alpha (TNF Alpha) blockade and Multiple Sclerosis (MS), exploring new avenues
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Multiple sclerosis (MS) is the most common disabling disease of the central nervous system (CNS) with a progressive neurodegenerative pattern. It is characterized by demyelination of white matter in CNS and apoptosis of oligodendrocytes. Tumor necrosis factor (TNF) alpha is a major cytokine in the pathogenesis of MS. However, the failure of TNF alpha inhibitors in preclinical and clinical trials disapproved of their use in MS patients. Nevertheless, failures and misses sometimes open avenues for new hits. In the later years, it was discovered that TNF signalling is mediated via two different receptors, TNFR1 and TNFR2, both of which have paradoxical effects. TNFR1 mediates demyelination and apoptosis, while TNFR2 promotes remyelination and neuroprotection. This explained the cause of the failure of non-selective TNF alpha-blockers in MS. It also enlightened researchers that repurposing the previously formulated non-selective TNF alpha-blockers using a receptor-selective approach could lead to discovering novel biologic agents with a broader spectrum of indications and better safety profiles. This review focuses on a novel premier TNFR1 blocker, atrosab, which has been tested in animal models of MS, experimental autoimmune encephalomyelitis (EAE), where it demonstrated a reduction in symptom severity. The early promise shown by atrosab in preclinical studies has given us hope to find another revolutionary drug for MS in future. Clinical trials are still going on which will finally decide whether this drug can be used as a better therapeutic agent for MS or not.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Journal of Neuroscience and Neuropharmacology.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neuroscience and Neuropharmacology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Maryam Zahid”
